carboxylate in human microsomes. Subsequently the lactone form was tested as a substrate in a panel of CYP450 and UGT enzymes known to metabolize the majority of clinically approved molecules. AR-67 was metabolized by CYP3A5, CYP3A4, CYP1A1 and CYP1A2, in order of activity. Extrahepatic UGT1A8 and UGT1A7 possessed at least 6-fold higher metabolizing activity than UGT1A1 and other UGT enzymes tested. CYP1A1 and UGT1A7 displayed Michaelis-Menten kinetics whereas CYP3A4, CYP3A5, and UGT1A8 displayed kinetics consistent with substrate inhibition. Chromatographic analysis of representative patient plasma and urine samples demonstrated the presence of AR-67 glucuronides and oxidized products in the urine, but only in very minimal amounts. We conclude that limited in vivo metabolism of AR-67 by UGT1A1 may partly explain the absence of AR-67 glucuronides in plasma and hypothesize that UGT1A8, and CYP3A mediated biotransformation within the GI epithelium may provide protective mechanisms against AR-67 gastrointestinal toxicity.
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INTRODUCTION
AR-67 (7-tert-butyldimethylsilyl-10-hydroxycamptothecin, also referred to as DB-67) is a 3 rd generation camptothecin analogue with improved lactone stability and cytotoxicity as compared to the FDA-approved camptothecins, irinotecan (Camptosar®) and topotecan (Hycamtin®) (Bom et al., 2000; Bom et al., 2001) . Camptothecins (CPTs) are S-phase specific topoisomerase-I poisons with potent anticancer activity. Since the isolation of the camptothecin molecule from the bark of the oriental tree, Camptotheca acuminata, the clinical development of CPTs has been hampered by the need to preserve the E-ring hydroxylactone, which is required for cytotoxicity (Hsiang et al., 1989; Giovanella et al., 2000) . For most CPTs, this lactone moiety undergoes reversible hydrolysis at physiological pH to form an apparently inactive carboxylate ( Fig. 1) . Thus, the overall anticancer activity of CPTs depends, in part, upon the dynamics of their individual lactone-carboxylate equilibrium. To some extent lactone stability of the analogues depicted in Fig. 1 has been credited to structural modifications of the camptothecin backbone. Specifically, the -R 3 hydroxyl group reduces carboxylate binding affinity to human serum albumin (Burke et al., 1995) and thus retards the hydrolysis process by eliminating this sink condition. In the case of AR-67, the increased lipophilicity afforded by its -R 1 tertbutyldimethylsilyl group also contributes to lactone protection via increased partitioning into lipid membranes (Burke et al., 1993) . The cumulative result is a drug that displays potent anticancer activity (Pollack et al., 1999) , with a high lactone AUC/total AUC ratio in vivo (87.5 ± 8.5%) (Arnold et al., 2010 ) as compared to other clinically approved CPTs (lactone AUC ratios of 30~76%) (Zamboni et al., 1999; van Riel et al., 2002) . Recent work from our laboratory has also demonstrated that the systemic clearance of the carboxylate form is 3.5-fold higher than that of the lactone, which ultimately leads to the apparently high lactone stability in plasma (Adane et al., 2010) . Whether the high carboxylate clearance is mediated by enzymes or transporters remains to be investigated.
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In addition to the non-enzymatic lactone hydrolysis, a number of pathways have been established in the metabolism of clinically approved camptothecins in vivo. Primary and secondary N-demethylated-and O-glucuronidated metabolites of topotecan have been isolated from the plasma and urine of patients at low levels, but have not been implicated in its pharmacodynamics or toxicity (Herben et al., 1998; Rosing et al., 1998) . Conversely, the metabolic pathways of irinotecan (CPT-11) are more complex. CPT-11 can undergo metabolic activation by carboxylesterases to form the 100 to1000-fold more potent SN-38 metabolite (Kawato et al., 1991; Tanizawa et al., 1994) . Moreover, CPT-11 undergoes sequential metabolism by members of the CYP3A family to form inactive ring-opened piperidine metabolites (Dodds et al., 1998) . O-Glucuronidation by hepatic UDP-glucuronosyltransferases (UGTs), in particular UGT1A1, deactivates the potent SN-38 metabolite (Rivory and Robert, 1995; Rosing et al., 1998) and together with hepatic organic anionic transport (Sugiyama et al., 1998 ) and diffusion of SN-38, provides the primary routes for SN-38 elimination. Accumulation of the highly cytotoxic SN-38 metabolite in the intestines and microfloral hydrolysis of the SN-38
glucuronide (Takasuna et al., 1996) is thought to be associated with the life-threatening diarrhea manifested in up to 25 % of patients receiving moderate to high dose CPT-11 therapy (Kawahara, 2006; Hu et al., 2010) . Thus, polymorphisms which impair the function of enzymes and transporters responsible for metabolizing and shuttling CPT-11 and its metabolites impact the overall exposure of patients to the active SN-38 metabolite and contribute to interpatient variability in SN-38 kinetics, dynamics and toxicity (Rouits et al., 2008; Cecchin et al., 2009; Innocenti et al., 2009) .
Given the structural similarities of AR-67 to other CPTs ( Fig. 1) , it was hypothesized that AR-67 would undergo metabolic glucuronidation and oxidation by the same enzymes responsible for their metabolism. Moreover, previous experience with SN-38 suggested that individual differences in AR-67 metabolic clearance, particularly via glucuronidation, may lead to severe delayed gastrointestinal toxicity in selected patients-beyond that typically exhibited by This article has not been copyedited and formatted. The final version may differ from this version. ice by dilution with 0.005 M HCl or 0.005 M NaOH, respectively. In all cases, the lactone working solutions were prepared and immediately used, whereas carboxylate working solutions were equilibrated on ice for 1 hr prior to use (Horn et al., 2006) . Final DMSO concentration in working solutions was adjusted to 4%. AR-67 is a highly protein-bound, highly lipophilic drug with relatively low aqueous solubility (Bom et al., 2000; Xiang and Anderson, 2002) . As a direct consequence, total protein content in all samples was keep constant at 0.25 mg/mL (except in range finding enzymatic experiments), as was the total DMSO content in reaction mixtures (0.2 %). The low solubility of AR-67 lactone limited the total AR-67 concentrations to 20 μM in enzymatic reactions.
This article has not been copyedited and formatted. The final version may differ from this version. Calibrators and QCs were processed as indicated below and analyzed by HPLC.
Sample processing and HPLC analysis. To quench reactions and precipitate proteins, all samples were mixed with a 4x volume of cold methanol (-80°C), vortexed (10 sec), centrifuged (2 min, 13,000 rpm, 4°C) and the methanolic supernatant was stored at -80˚C. For HPLC analysis, methanolic supernatants were diluted with an equivalent volume of 0.15 M ammonium acetate buffer containing 10 mM tetrabutylammonium dihydrogen phosphate (TBAP) (pH 6.5)
prior to a 50-µL injection (Horn et al., 2006) .
HPLC analysis was performed on a Shimadzu LC system (Shimadzu Inc., Atlanta, GA) equipped with a guard-protected Nova-Pak ® C18 column (4 μm; 3.9 x 150 mm) using gradient elution. Mobile phase (1 mL/min flow rate) consisted of varying ratios of Solvent A (0.15 M ammonium acetate buffer containing 10 mM TBAP adjusted to pH 6.5) and Solvent B (acetonitrile). Characterization of AR-67 glucuronides. AR-67 glucuronide metabolites were prepared by scaled-up reactions of AR-67 lactone (5 µM) with UGT1A8 (1 mg/ml) but contained 5 % DMSO. Glucuronide lactone and carboxylate interconversion: After incubating 60 min, UGT1A8
reactions were quenched and treated according to the general workup procedure. Aliquots (40 µL) of the methanolic supernatant were reacted with equal volumes of 1 M HCl or 1 M NaOH for an additional 60 min prior to HPLC analysis to assess the interconversion of the glucuronide between lactone and carboxylate analytes at pH 3 and pH 11, respectively. Excitation/emission scans: After 60 min incubation reaction, samples were quenched and processed for HPLC analysis. Gradient flow was halted upon analyte detection within the fluorescence detector flow cell so that peak specific emission (excitation at 380 nm) and excitation (emission set 450 nm for putative glucuronide analytes, 560 nm for AR-67 carboxylate and lactone) spectra could be collected. After scan completion, flow was resumed and process repeated for all fluorescing analytes within the sample. Mass spectral analysis: For MS and MS/MS analysis the putative glucuronide metabolites were isolated by SPE. After overnight incubation, the reaction mixture was applied to a 1 mL Waters HLB Oasis SPE column (30 mg), which had been previously conditioned and equilibrated (1 mL methanol then water, respectively). After loading, the glucuronides were eluted with 1 mL 5 % methanol in water (fraction #1), AR-67 carboxylate and lactone were eluted with 1 mL methanol (fraction #2). The fractions were dried at room temperature under N 2 , and reconstituted in 1 mL methanol. Reconstituted fractions were
This article has not been copyedited and formatted. The final version may differ from this version. analyzed by HPLC for content. Fraction #1 was then treated with an equal volume of 0.15 M formic acid on ice for 1 hr, an aliquot was analyzed by HPLC to ensure complete conversion to the lactone form of the analyte. The acidified sample was then infused at 10 µL/min through an ESI into the API 2000, the parameters were optimized for detection of the 653 m/z molecular anion of AR-67 lactone glucuronide. Subsequently, a 100-900 m/z mass spectra, and 653 m/z product ion spectra were collected. Carboxylate and lactone glucuronide stability and recovery:
AR-67 glucuronides were generated and isolated as described above for spectral analysis. The
Fraction #1 residue was dissolved in 500 µL 0.005 M NaOH. A 250 μL aliquot was treated with 2 volumes of 0.005 M HCl, to prepare the lactone glucuronide; whereas an additional aliquot was treated with 2x vol of 0.005 M NaOH to maintain the carboxylate glucuronide (both equilibrated 2 hrs on ice). Analysis of these equimolar solutions allowed a relative response ratio between the two glucuronides forms to be calculated from their respective peak areas.
These solutions were then used to spike methanol, human plasma, and human urine with either the lactone or the carboxylate glucuronide (n=3/analyte/matrix). Following the clinical procedures used in the collection and storage of in vivo samples (Arnold et al., 2010) , the spiked plasma samples were immediately processed. The resulting methanolic supernatant was analyzed for initial levels of AR-67 glucuronide, then stored at -80ºC with repeated HPLC analysis 3 days, 1 week, 3 weeks, and 4 weeks after storage. Aliquots of the spiked urines were processed and analyzed immediately for comparison to remaining amounts which were kept at ambient temperature for 24 hr prior to processing and analysis. Differences in analyte levels between spiked methanol samples and processed plasma samples were used to estimate individual analyte recovery.
Characterization of oxidized AR-67 metabolites.
For the following assays CYP3A5 reaction mixtures were used to generate the oxidized metabolites. AR-67 lactone (5 µM) and recombinant protein (1 mg/mL) were reacted at 37°C in incubations containing 5 % DMSO.
This article has not been copyedited and formatted. The final version may differ from this version. wavelengths. Mass spectral analysis: After overnight reaction, the mixture was applied to a 1 mL Waters HLB Oasis SPE column (30 mg), conditioned and equilibrated as described earlier.
After loading, 1 mL of 5 % methanol in water (fraction #1) was applied, followed by 1 mL methanol (fraction #2). The fractions were dried at room temperature under N 2 , reconstituted in methanol at 1/5 original applied volume, and analyzed by HPLC. Fraction 2 contained all fluorescing components. The reconstituted sample was then infused (10 µL/min) through the ESI source using optimized voltages. Stability and recovery of major oxidized metabolite:
Oxidized AR-67 metabolites were generated and isolated as described above for spectral analysis. The Fraction #2 residue was dissolved in 500 µL DMSO and used to spike methanol, human plasma, and human urine (n=3/analyte/matrix). Samples were processed, stored and analyzed in a time dependent manner as described above for glucuronide stability. Similarly, recovery of the major CYP3A5 metabolite was calculated from differences in analyte levels between spiked methanol samples and processed plasma samples.
Metabolite identification in clinical samples.
A Phase I study to determine the maximum tolerated dose of AR-67 has been recently completed wherein qualified consenting patients received IV treatment with 1.67 to12.4 mg/m 2 of AR-67 for five consecutive days at the beginning of 21 day cycles (Arnold et al., 2010) . Cycle 1, Day 1 and Day 4 plasma samples (predose, 5 min, 45 min, 65 min, 1.5 hr, 2 hr, 4 hr, 6 hr, 8 hr and 24 hr after start of infusion)
were collected for AR-67 pharmacokinetic analysis, as well as Day 1 and Day 4 total urine.
Plasma samples were processed at the bedside and the methanolic supernatants stored at -80 ºC. Urine, which was collected for 24 hrs after infusion, was processed upon receipt, and the (Arnold et al., 2010) .
To investigate the metabolism of AR-67 in vivo, the supernatants from the 45 min plasma samples (i.e., AR-67 C max ) and the urine samples derived from 13 patients receiving doses of 7.5 mg/m 2 or higher were analyzed by gradient HPLC for the presence of peaks chromatographically similar to those obtained in AR-67 metabolic reactions with UGT and CYP enzymes. Based on the single sample analyses results, one patient was determined to possess "non-representative" levels of AR-67 metabolites. All of the plasma sample supernatants from this patient were analyzed by gradient HPLC to generate time vs. concentration plots for the glucuronide metabolites.
Quantitation, kinetic and statistical analysis. Weighted regression of peak areas to nominal matrix-matched calibrator concentrations yielded linear calibration curves for the lactone and carboxylate analytes, which were used to interpolate AR-67 lactone and carboxylate quantities in experimental samples. Total AR-67 was derived by addition of these two values. In instances where experimental analyte concentrations exceeded 300 ng/mL, the original experimental methanolic supernatant was diluted with blank supersomal methanolic supernatant, and reanalyzed as a 50-µL injection after mixing 1:1 with mobile phase buffer.
As no commercial standards were available, metabolite peak areas were used to quantitate relative enzymatic activities, kinetic parameters, metabolite stability and metabolite recovery. In quantitating carboxylate and lactone glucuronides, a molar response ratio (lactone /carboxylate) of 0.54 was estimated using the peak areas of equimolar carboxylate and lactone glucuronide solutions. Following chromatographic analysis with fluorescence detection this ratio was used to convert the carboxylate glucuronide peak areas to the lactone glucuronide peak areas and a total area was reported. When assessing the presence of glucuronides in patient samples, the "ng/mL equivalent" values for these metabolites have been reported and were
This article has not been copyedited and formatted. The final version may differ from this version. Microsomal and enzymatic activities were calculated from early time points exhibiting linear kinetics for metabolite formation. Recombinant enzyme kinetics were described by the Michaelis-Menten (Eq. 1) or the substrate inhibition models (Eq. 2) as indicated by the plots of their metabolic velocity (V) against free substrate concentrations (S).
(Eq. 1)
These plots were fitted using nonlinear least-square regression analysis (Prism Ver. 5.02, GraphPad Software Inc., San Diego, CA) to estimate values for the Michaelis-Menten constant (K m ), the maximum velocity (V max ), and the substrate inhibition constant (K si ), when applicable (Houston and Kenworthy, 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. intestinal microsomes demonstrated significant metabolic activity toward AR-67 lactone (activity of 302,100 ± 14,900 total metabolite peak area/min/mg protein). HPLC analysis of this reaction mixture, demonstrated the appearance of two fluorescing analytes, chromatographically separable from AR-67 lactone and its carboxylate form. These two metabolites were thought to correspond to the glucuronides of AR-67 carboxylate and lactone, respectively, as they exhibited greater corresponding polarity than either the lactone or its hydrolysis product. Under
Phase I oxidative conditions both HLM and HIM metabolized AR-67 lactone to chromatographically similar fluorescing products (activity of 241,200 ± 10,700 and 316,000 ± 8,500 primary metabolite peak area/min/mg protein, respectively), which included an early eluting product associated with the presence of NADPH, as well as at least one major and one minor polar fluorescing metabolite. Thus, qualitative assessment of the in vitro oxidation and glucuronidation of AR-67 lactone in HLM and HIM showed that oxidation is likely to be the major biotransformation pathway for AR-67 in the liver, but that both AR-67 oxidation and glucuronide conjugation may occur in the intestine.
Enzymatic metabolism of AR-67 in supersomes.
Given that AR-67 was glucuronidated in microsomal systems, further investigations were conducted using single recombinant enzymes to identify the proteins involved in the biotransformation process. In time dependent studies AR-67 lactone (0.2 µM) glucuronidation was studied in incubations containing human recombinant UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, or 2B17. Among these, only UGT1A1, 1A3, 1A7, 1A8, 1A9, and 2B4 were capable of conjugating AR-67. The activities of these enzymes for total metabolite formation are listed in Table 1 , with UGT1A8 and 1A7 displaying greater than 6x the velocity of the other active UGT enzymes under linear conditions.
Qualitatively, all active UGT enzymes yielded the same two polar peaks, which were observed in HIM and HLM reactions.
This article has not been copyedited and formatted. The final version may differ from this version. were capable of converting AR-67 lactone to more polar, fluorescing species in a timedependent manner. Again, these Phase I reactions also gave rise to an early eluting peak but this was also present in control reactions of blank supersomes containing an NADPH regenerating system, but absent in those devoid of oxidative cofactors. The relative activity of these enzymes toward the lactone, as assessed by product formation under linear conditions, was CYP3A5>>CYP1A1≈CYP3A4> CYP1A2 (Table 1) . Qualitatively, the appearance of the major and minor metabolite peaks resulting from the reactions of CYP1A incubations were similar, but were relatively more hydrophilic than the metabolites arising from CYP3A4, CYP3A5
and microsomes.
Subsequently we conducted concentration-dependent studies with AR-67 concentrations ranging between 0.05 and 20 μM. Time points of 5 min and 2 min, which were within the linear range, were selected for UGT and CYP incubations, respectively. Under these conditions AR-67 lactone underwent limited chemical hydrolysis (≤ 6 % conversion to carboxylate), 81.3 ± 0.1 % binding to supersomes, and conversion to a single metabolite in Phase I reactions. Substrate concentrations above 20 μM were not investigated; due to the limited solubility of AR-67 lactone in the 4% DMSO working solutions. Plots of the metabolite formation rates against the free (unbound) lactone substrate concentrations are displayed in Fig. 2 (Fig. 3A) . To gain additional information regarding the structural position of the glucuronide moiety, AR-67-glucuronides obtained following exposure to UGT1A8 were acidified or alkylated by the addition of 1M HCl or 1M
NaOH, respectively. As demonstrated in Fig. 3B , exposure of the glucuronide mixture to acidic conditions converts the glucuronide to the lactone form, while exposure to basic pH leads to the conversion to the carboxylate form. In both cases, the parent AR-67 lactone and carboxylate peaks are minor. This corroborates the identity of the "3" labeled peak as an AR-67 carboxylate O-glucuronide and the "4" labeled peak as an AR-67 lactone O-glucuronide. The capacity of the glucuronide to interconvert between the lactone and carboxylate forms while maintaining the glucuronide moiety limits conjugation to sites not directly involved in carboxylate condensation.
In other words, the presence of either an acyl-glucuronide (i.e., 21-O-glucuronide) or a 22-Oglucuronide would necessarily undergo cleavage during condensation under acidic conditions to form AR-67 lactone. However, a trace amount of AR-67 lactone is noted within the chromatogram of the acidified sample and suggests that either a C-21 or C-22 glucuronide may be formed on AR-67 carboxylate, which could have arisen from lactone hydrolysis. To assess the spectral characteristics of the four peaks observed in Fig. 3A , stop-flow HPLC gradient analysis of the UGT1A8 reaction mixture supernatant was used to allow collection of excitation and emission scans. Both glucuronide forms possessed excitation maxima at 390 nm and emission maxima at 440 nm, as compared to AR-67 carboxylate and lactone which possess 380 nm excitation and 560 nm emission maxima wavelengths. This distinction is depicted in Fig.   3C , which highlights the differences between the lactone and lactone-glucuronide. This spectral Solid phase extraction was used to separate the presumed glucuronide peaks, which are labeled "3" and "4" in Fig. 3A and 3B. Treatment of this fraction with formic acid converted the mixture to only the "4" metabolic product. Subsequent MS and MS/MS analysis of this acidified fraction revealed a prominent 653 m/z, and an MS/MS fragmentation pattern consistent with an AR-67 lactone glucuronide (Fig. 3D) . Collectively, these data suggest that the AR-67 lactone glucuronide is formed at the phenolic hydroxide with some minor fraction being an acylglucuronide (Fig. 3E) .
Characterization of oxidized AR-67 metabolites. Emission and excitation scans collected on
CYP3A5 products displayed 380 nm excitation maximums, and 540 nm emission maximums.
These were not significantly shifted from AR-67 with 380 and 560 nm excitation and emission maximums, respectively. Processing incubation reactions through an SPE column did not allow for separation of oxidized metabolites from AR-67 carboxylate and lactone. Thus, MS analysis was essentially conducted on a SPE purified reaction mixture. Molecular and fragment ions of AR-67 lactone (substrate with MW=478 g/mol) and carboxylate (hydrolysis product with MW=496 g/mol) were prominent amidst the 400-700 m/z range expected for oxidized AR-67 (Fig. 4A) . Product ion scans of 493.2, and 465.1 m/z revealed evidence for AR-67 hydroxylation and subsequent de-alkylation products ( Fig. 4B and 4C ).
In vivo identification of AR-67 metabolites in patients. A gradient HPLC with fluorescence
detection assay was used to analyze plasma and urine samples collected from patients enrolled in a Phase-I study (Arnold et al., 2010) . Assay performance was assessed using UGT1A8 and CYP3A5 formed metabolites which were spiked into human plasma and urine. Recovery of both the carboxylate and lactone glucuronides from spiked plasma by methanolic quenching was 100
This article has not been copyedited and formatted. The final version may differ from this version. oxidative metabolite from spiked plasma was found to be 88.95 ± 3.34 % with stability of 100.65 ± 4.09 % over 28 days in methanolic supernatants stored at -80 ºC. Stability in urine kept at room temperature for at least 24 hrs was 91.04 ± 6.78 %.
Plasma from patients receiving 7.5-12.4 mg/m 2 AR-67 did not demonstrate the presence of circulating glucuronide metabolites or CYP3A dependent-oxidation products, except in the case of one patient we designated as "non-representative" (Fig. 5A) . The carboxylate and lactone glucuronides in plasma of the "non-representative" patient were semi-quantitated as ng/mL equivalents of carboxylate or lactone. The sum of these equivalents was plotted against time to show an approximate total AR-67 glucuronide exposure for this patient (Fig. 5B ). There were no apparent differences in the plasma concentrations of total AR-67 or total Oglucuronidated metabolites between days 1 and 4 in this patient. Based on the HPLC analyses, the total amount of AR-67 in the 24 hr urine samples from representative patients was calculated to be 3.02 % (± 1.28 %) of dose administered, whereas the non-representative patient excreted 11.17 % of dose. All urine samples from these patients contained varying, but limited amounts of oxidized and glucuronidated AR-67 metabolic products (Fig. 5A ).
This article has not been copyedited and formatted. The final version may differ from this version. blood counts and diarrhea. The latter toxicity is related to the intrinsic cytotoxic activity of CPTs toward the rapidly proliferating GI epithelium and is exacerbated in individuals with low metabolizing efficiency. Although, in the course of the first AR-67 Phase I study the dose limiting toxicities were of hematopoietic origin, diarrhea was not observed (Arnold et al., 2010) . This finding prompted us to initiate studies to determine the pathways of AR-67 metabolism, as well as to analyze patient samples for evidence of potential metabolites.
HLM and HIM studies demonstrated that under experimental conditions AR-67 lactone, but not carboxylate, could undergo oxidative metabolism (Table 1) . This confirmed previous reports of NADPH-dependent AR-67 metabolism by mouse and human liver microsomes (Yeh et al., 2009 ). This, however, is not unique to AR-67 as preferential lactone biotransformation was observed in liver microsomes reacted with CPT-11 (Lokiec et al., 1996; Haaz et al., 1998; Rosing et al., 1998; Santos et al., 2000) . The products resulting from HLM and HIM reaction with AR-67 lactone were attributed primarily to CYP3A metabolism, due to their chromatographic similarity with products formed following AR-67 incubation with recombinantly expressed CYP3A4 and CYP3A5. Although we did not attempt to estimate relative activity factors in this work, we anticipate that the subpopulation of patients lacking CYP3A5 activity may have lower overall oxidative clearance (Thelen and Dressman, 2009 ). Nevertheless, metabolites were observed following incubation in liver and intestinal microsomal systems suggesting the potential for oxidative metabolic clearance in both hepatic and GI tissue.
HLM and HIM reactions optimized for glucuronidation demonstrated that HIM enzymes had the highest activity toward AR-67 lactone, which was almost 10-fold higher than that of HLM. The activity toward AR-67 lactone in HIM was 7-fold higher than the activity toward AR-67
This article has not been copyedited and formatted. The final version may differ from this version. carboxylate, but the activities observed in HLM were the same (Table 1) . This is in contrast to previous findings with SN-38 that demonstrated no difference in the glucuronidation of lactone and carboxylate in HLM (Haaz et al., 1997) . In all cases, two glucuronide products were formed and were chromatographically identical to those produced by recombinant UGT enzymes.
These two products were later identified as the carboxylate and lactone glucuronides of AR-67.
The lactone glucuronide was the predominant product in all reactions, even with AR-67 carboxylate as the substrate, suggesting that enzymatic interaction occurred through formation of the AR-67 lactone in AR-67 carboxylate incubations. Although relative activity factors were not calculated, the observed in vitro activity and expression patterns of the active UGT enzymes allow us to infer that UGT1A8 may account for a majority of the HIM activity (Tukey and Strassburg, 2000) . In contrast, the HLM activity must be the cumulative effect of UGT1A1, 1A3, 1A9 and 2B4. Collectively, the data suggest the potential for low level glucuronidation mediated clearance in the liver with additional capacity within the GI tract.
Studies with all the commercially available recombinant UGT enzymes showed that UGT1A8 and 1A7 activity toward AR-67 was 6-fold higher than 1A3, 1A1, 1A9 and 2B4 (Table   1 ). It should be noted, however, that in the recombinant enzyme reactions we did not evaluate the effect of fatty-acid-free human serum albumin, which has been shown to increase UGT1A9, UGT2B7, and CYP2C9 activities (Rowland et al., 2008a; Rowland et al., 2008b) . Interestingly, UGT1A8 and UGT1A7 are extrahepatic with distinct GI expression, as opposed to UGT1A3 and UGT1A1, which are expressed in liver and GI tract (Tukey and Strassburg, 2000; Nakamura et al., 2008) . This pattern of activity reflected the microsomal observations and leads us to hypothesize that increased activity and localization of UGT1A8 in the GI tract might provide a protective mechanism against AR-67 cytotoxicity in GI epithelium. In contrast, the diminished activity of UGT1A1 and other UGT enzymes expressed in the liver could in part explain the absence of AR-67 glucuronide metabolites in the plasma of almost all patients. Concentrationdependent studies showed that UGT1A8 displayed strong substrate inhibition kinetics (K si Given the presence of several hydroxyl groups on both forms of AR-67 ( Fig. 1) there is potential for the formation of multiple glucuronide products. Incubation of AR-67 lactone with all active UGT enzymes resulted in two products with greater hydrophilicity than either AR-67 lactone or carboxylate. These products were tentatively identified as the carboxylate and lactone 10-O-glucuronides (Fig. 3) following studies of β -glucuronidase treatment, pH modulation, and emission wavelength shifts (Rosing et al., 1998) . The glucuronide structures were subsequently confirmed with MS/MS analysis (Fig. 3D) .
A panel of CYP450s, including those known to metabolize approximately 90 % of drugs (Guengerich, 2006) , as well as those known to metabolize topotecan and irinotecan (Lokiec et al., 1996; Haaz et al., 1998; Rosing et al., 1998; Santos et al., 2000) , were used to evaluate AR-67 metabolism. Of these, only the CYP3A and CYP1A enzymes were found to transform AR-67 lactone ( Table 1 ). The products from the CYP3A enzymes were distinctly more hydrophobic than the CYP1A products, and matched those formed in microsomes. Our preliminary MS studies provide evidence for hydroxylated and dealkylated products of AR-67 from CYP3A
reactions, which occur on the camptothecin ring system. However, further work is required to fully determine the structures of metabolites arising from CYP3A and CYP1A. Concentrationdependent studies showed that under experimental conditions the CYP3A enzymes displayed substrate inhibition kinetics, while CYP1A1 displayed classic Michaelis-Menten kinetics.
Chromatographic analysis demonstrated that twelve of thirteen patients, who received the maximum tolerated dosage or higher, had no detectable metabolites in their plasma, and only minimal metabolites in their urine (Fig. 5A ). Quantitative AR-67 analysis in the urine from these representative patients indicated that 3.02 % (± 1.28 %) of the administered AR-67 dose was excreted in the urine as unchanged drug. A "non-representative" patient displayed much higher amounts of AR-67 metabolites in the plasma and urine (Fig 5A) , and excreted 11.17 % of dose as unchanged AR-67 in the urine. The metabolites present in this patient included AR-67
This article has not been copyedited and formatted. The final version may differ from this version. glucuronides, CYP3A products, CYP1A product and several minor unidentified analytes. The difference in the plasma and urine metabolite levels between this patient and the rest of the study subjects could not be attributed to metabolite stability or differences in sample processing.
Collectively, the data suggest that the bulk of AR-67 is processed through the liver and is efficiently transferred, as unchanged drug or as metabolites, into the bile for elimination. Little is known about AR-67 transport, as only few transporters have been tested for their capacity to translocate AR-67 (Milewska et al., 2009 (Smith et al., 2006) . To help us construct a mechanistic framework for understanding AR-67 kinetics we present a schematic depicting our current knowledge of enzymes and transporters implicated in AR-67 disposition (Fig. 6 ). As the primary clearance pathways appear to be hepatic, we have omitted potential interactions with kidney transporters. Future studies will be necessary to determine if interpatient variability in the GI expression of CYP3A4, CYP3A5, UGT1A7 or UGT1A8 are prognostic factors for increased gastrointestinal toxicities. However, this may be more relevant if oral formulations of AR-67 are sought or if dosing schedules exploring the efficacy of less frequent, but higher dosage levels are tested in the clinic.
This article has not been copyedited and formatted. The final version may differ from this version. (Burke et al., 1995) . The lactone form of AR-67 readily diffuses into hepatocytes whereas the carboxylate entry may transporters (e.g., P-glycoprotein (P-gp) and BCRP) into the bile. Intact AR-67 may also be effluxed into the bile. AR-67 glucuronides that are carried into the intestinal lumen via the bile may be hydrolyzed by bacterial enzymes (e.g., bacterial beta-glucuronidase (BG)) to form AR-67. The lactone moiety may diffuse into the intestinal epithelium or may precipitate in the lumen.
Inside the intestinal epithelium AR-67 may undergo oxidative metabolism or phase-II conjugation. Intact AR-67 and metabolites may be actively effluxed back into the intestinal lumen. Intact drug may also diffuse into the circulation. The lack of metabolites in the plasma of most patients, but their presence in the urine indicates that low amounts of metabolites may be effluxed into plasma but these are rapidly cleared by the kidney.
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